## [Singapore Pharmaceutical Registration: What You Need to Know](/blog/singapore-pharmaceutical-registration-what-you-need-to-know) October 24, 2025 ![Singapore Pharmaceutical Registration: What You Need to Know]() 3 min read - [Medicinal Products](/blog-main-categories/medicinal-products) - [Regulatory Affairs](/blog-main-categories/regulatory-affairs) ## Market Overview Singapore pharmaceutical registration is becoming increasingly important as the country strengthens its role as a regional pharma hub. The market was valued at approximately USD 7.40 billion in 2024 and is projected to nearly double to USD 12.19 billion by 2033, with a CAGR of 5.5%. The pharmaceuticals market revenue is expected to grow from USD 1.82 billion in 2025 to USD 2.42 billion by 2030, particularly buoyed by oncology treatments with a CAGR of 5.86%. This underscores Singapore’s rising importance as a pharmaceutical hub for both innovative and generic medicines, supported by strong regulatory oversight and government R&D investment. Singapore hosts world-class manufacturing facilities, cutting-edge research institutes, and the **Health Sciences Authority (HSA)** the country’s regulatory body responsible for ensuring the safety, efficacy, and quality of drugs, medical devices, and health products. ## Singapore Pharmaceutical Registration: Product Classification (HSA)  **Therapeutic Products (TPs)**: Prescription-only, pharmacy-only, and general-sale (OTC) medicines (small molecules and biologics). **Application Types:** - **NDA:** New Drug Application for novel entities/indications. - **GDA:** Generic Drug Application; requires bioequivalence data. **Evaluation Routes (where eligible):** Full, Abridged, Verification, and Verification CECA increasingly leveraging approvals from reference authorities to accelerate reviews. ## Registration Process Flow 1. Determine Product Scope & Pathway 2. Appoint Local MAH 3. GMP & Quality Readiness 4. Prepare Dossier 5. Submit Online via PRISM 6. HSA Screening & Evaluation 7. Approval & Listing 8. Post approval Changes - **Determine Product Scope & Pathway:** Identify TP class and choose NDA/GDA and Full/Abridged/Verification/Verification CECA route. TPs already approved by reference agencies, verification or abridged routes can be available for quicker and smoother approval - **Appoint Local MAH:** A Singapore-registered company serves as the **Marketing Authorization Holder** and HSA interface. - **GMP & Quality Readiness:** Ensure manufacturing facilities meet GMP; provide evidence (e.g., inspection reports). Also, a valid PICs (Pharmaceutical Inspection Co-operation Scheme) GMP certificate can be incorporated, if available. - **Prepare Dossier (ICH CTD/ACTD):** Modules 1–5, incorporating Singapore-specific labeling (SGPI/PIL), pharmaceutical development, process validation, manufacturing sites, risk management etc. where applicable. - **Submit Online via PRISM:** File application, pay fees, and upload documents via PRISM. Based on the variants, each dosage form and strength require a separate. - **HSA Screening & Evaluation:** Conduct administrative and scientific review; manage queries within stipulated timelines. The HSA drug approval Singapore process may also involve additional technical or administrative information requests. - **Approval & Listing:** Upon drug registration Singapore, companies can secure product licenses, finalize labeling, and fulfill post-approval obligations (variations, safety reporting, renewals). - **Post approval Changes:** Applicant’s keep the HSA informed on any changes to the TP (quality, safety and efficacy) throughout the product lifecycle. ## Freyr’s Case Study: Registration Support for an Intravenous Product in Singapore  **Context:**  A U.S.-based company sought rapid approval of an intravenous product (intravenous artesunate) in Singapore. **Services Provided** - Regulatory planning: feasibility assessment, registration strategy for HSA, and dossier scoping. - Documentation gap analysis. - Preparation of Module 1. - Application filing via PRISM and monitoring. - Uploading of documentation (all modules) into PRISM and splitting/processing of files and their size as per HSA requirements. - Compilation of query responses and uploading into PRISM - Liaison and follow-up with HSA. - MAH services and query resolution. **Challenges** - Demonstrating product quality, safety, and efficacy. - Coordination across multiple regulatory jurisdictions. - Meeting Singapore-specific regulatory requirements. **Solution Offered** - Tailored regulatory strategy with a dossier roadmap. - Detailed gap analysis and high-level document review. - Compilation and submission of required documents. - Rapid response to HSA queries and ongoing support through approval. **Benefits** - Accelerated registration due to comprehensive and accurate submissions. - Cost and time savings through compliance alignment. - Increased likelihood of approval. - Efficient query resolution with technical/regulatory expertise. - Full MAH support until approval. - On-demand regulatory support as needed. ## Summary Table  | **Category** | **Details** | |---|---| | Market Size & Growth | USD 7.4B (2024) → USD 12.2B (2033), CAGR ~5.5% | | Oncology Segment | Strong demand; part of Singapore’s pharma growth story | | Product Types | NDA, GDA | | Evaluation Routes | Full, Abridged, Verification, Verification CECA | | Registration Key Steps | Scope ► MAH ► GMP ► Dossier ► Submit via PRISM ► HSA Review | | Case Study Focus | Fast-track IV product registration via full-service support | ## Conclusion Freyr’s expertise in Singapore pharmaceutical registration — from dossier preparation to HSA liaison — enables pharma companies to streamline submissions, accelerate approvals, and gain a competitive edge in this dynamic market. Contact Freyr today.